PD-1+ and Tfh Cells Are Responsible for Persistent HIV-1 Transcription in Treated Aviremic Individuals

1Riddhima Banga, 1Francesco Andrea Procopio, 1Alessandra Noto, 2Georgios Pollakis, 3Matthias Cavassini, 1Khalid Ohmiti, 4Jean-Marc Corpataux, 5Laurence de Leval, 1,6Giuseppe Pantaleo and 1Matthieu Perreau

1Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland, 2Department of Clinical Infection, Microbiology and Immunology (CIMI), Institute of Infection and Global Health (IGH), University of Liverpool, Liverpool, UK, 3Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland, 4Service of Vascular Surgery, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland, 5Institute of Pathology, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland, 6Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland

$Correspondence should be addressed to:
Dr. Matthieu Perreau matthieu.perreau@chuv.ch
or
Prof. Giuseppe Pantaleo giuseppe.pantaleo@chuv.ch

Running title:
Keywords:
Abstract word count: 250
Text character count:
Non standard abbreviation list: Abs, antibodies; APC, Allophycocyanin; ART, antiretroviral therapy; CCR7, C-C chemokine receptor type 7; CM, central memory; DN, dual negative; ECD, Energy Coupled Dye (Phycoerythrin-Texas Red conjugate); ECL, electrochemiluminescence; MAbs, monoclonal antibodies; PB, Pacific Blue; PD-1, Programmed-Death-1; PECy7, Phycoerythrin-Cyanine7 conjugate; PerCP, Peridinin
Chlorophyll-A Protein; PerCP-Cy5.5, Peridinin Chlorophyll-A Protein-Cyanin5.5 conjugate;
RPMI, Roswell Park Memorial Institute medium; RT-PCR, reverse transcriptase-polymerase
chain reaction; Tfh, T follicular helper T cells; TM, transitional memory; VOA, viral
outgrowth assay.
Abstract

The mechanisms responsible for the persistence of HIV-1 after many years of suppressive antiretroviral therapy (ART) have been partially elucidated. Most of the studies investigating HIV-1 persistence have been performed in blood although it is well known that germinal centers (GCs) within lymph nodes (LNs) serve as primary sites for HIV-1 replication. We sought to identify the memory CD4 T cell population(s) in blood and LNs responsible for the production of replication competent and infectious HIV-1 and for active and persistent virus transcription in ART treated (1.5-14 years) aviremic (<50 HIV RNA copies/ml) individuals. We demonstrate that LN PD-1⁺ CD4 T cells which are composed of about 65% T follicular helper cells as defined by the expression of CXCR5 and PD-1, are the major source of replication competent HIV-1 and of infectious virus compared to any other (CXCR5⁻PD-1⁻, CXCR5⁺PD-1⁻) blood or LN memory CD4 T cell populations. LN PD-1⁺ cells accounted for 46% and 96% of the total pools of memory CD4 T cells containing inducible replication competent and infectious virus, respectively. Notably, higher levels of cell-associated HIV-1 RNA were present in LN PD-1⁺ cells after long-term (up to 12 years) ART as compared to the other memory CD4 T cell populations. These results indicate that LN PD-1⁺ cells serve as the major CD4 T cell compartment in blood and LNs for replication competent and infectious HIV-1 and for active and persistent virus transcription in long-term ART treated aviremic individuals and may represent a major obstacle to HIV-1 functional cure.
Introduction

The main mechanisms that hinder HIV-1 eradication despite effective ART are 1) the existence of long-lived latently HIV-1 infected resting memory CD4 T cells and/or 2) the existence of residual virus replication that replenishes the HIV-1 latent cell reservoir\textsuperscript{1-6}. Estimates of the HIV-1 latent reservoir half-life in the blood indicate that as long as 70 years of ART might be required for full eradication of the latent reservoir\textsuperscript{5}. A pioneering study identified central memory (CM; defined by CD45RA\textsuperscript{-}CCR7\textsuperscript{+}CD27\textsuperscript{+}) and transitional memory (TM; CD45RA\textsuperscript{-}CCR7\textsuperscript{-}CD27\textsuperscript{+}) CD4 T cells as major cellular compartments of the latent HIV-1 reservoir in blood\textsuperscript{6}. More recently, memory CD4 T cells with stem-cell like properties were identified as a novel but minor latent HIV-1 reservoir\textsuperscript{7}. Therefore, numerous strategies are currently being evaluated to target and kill HIV-1 infected cells to ultimately find a cure.

Blood contains only 2% of the total lymphocytes which reside predominantly within lymphoid organs and lymphocyte populations within the tissues are phenotypically and functionally distinct from those in blood\textsuperscript{8}. The recently described T follicular helper cells (Tfh) illustrate this difference\textsuperscript{9,10}. In this regard, we have recently shown that LN Tfh cells defined by the expression of CXCR5 and PD-1 and to a lesser extent memory CXCR5\textsuperscript{+}PD-1\textsuperscript{+} CD4 T cells serve as the major CD4 T cell compartments for HIV-1 replication, production and infection in viremic HIV-1-infected individuals\textsuperscript{11}. Since, cytotoxic CD8 T cells have limited access to GCs\textsuperscript{12} and antiretroviral drug penetration might be reduced in lymphoid tissue\textsuperscript{13}, HIV-1-infected Tfh cells residing in GCs may represent a major barrier for functional HIV-1 cure and eradication. However, no data are currently available on the role of Tfh cells as a preferential cell compartment for replication competent virus in long-term treated aviremic HIV-1-infected individuals.

In order to address this issue, we have investigated the distribution of replication competent and infectious virus within different memory CD4 T cell populations sorted on the basis of the expression of CXCR5 and PD-1, i.e. CXCR5\textsuperscript{+}PD-1\textsuperscript{-}, CXCR5\textsuperscript{-}PD-1\textsuperscript{-} and PD-1\textsuperscript{+} memory CD4 T cell populations, isolated from blood and LN of long-term treated aviremic HIV-1-infected individuals. The results shown in the present study demonstrate that LN PD-1\textsuperscript{+}/Tfh cells of long-term ART treated aviremic HIV-1-infected individuals are the major source of replication competent and infectious HIV-1 and the cell compartment responsible for active and persistent virus transcription.
Results

Characterization of CD4 T cell populations

We simultaneously collected blood and LNs of 23 ART treated aviremic HIV-1-infected individuals. The 23 individuals studied had a documented diagnosis of HIV-1 infection between 2 and 27 years and duration of ART between 0.3 and 14 years (Table 1). Mononuclear cells isolated from blood and LNs were then stained with CD3, CD4, CD45RA, CXCR5 and PD-1 antibodies. Five populations of memory (CD45RA⁻) CD4 T cells were identified on the basis of the expression of PD-1 and CXCR5, *i.e.* CXCR5⁻PD-1⁻ dual negative cells (DN), single CXCR5⁺ (CXCR5⁺PD-1⁻) cells, single PD-1⁺ (CXCR5⁻PD-1⁺) cells, dual CXCR5⁺PD-1⁺ and CXCR5⁺PD-1⁺ high CD4 T cells (Supplementary Fig. 1a). The latter two populations correspond to Tfh cells on the basis of their phenotypic, transcription factor and functional profiles. Consistent with previous study, Tfh CXCR5⁺PD-1⁺ cells were significantly (*P* < 0.05) enriched in LNs (7.48%) as compared to blood (1.28%) (Supplementary Fig. 1a,b) and Tfh CXCR5⁺PD-1⁺ high cells were only detected in LNs representing about 2.03% of LN memory CD4 T cells (Supplementary Fig. 1a,b). Because of the very low percentage of PD-1⁺ CD4 T cells in LNs and particularly in blood, and limited number of LN cells isolated, it was not possible to sort individual PD-1⁺ cell populations. Therefore the total PD-1⁺ CD4 T cell population was sorted for the viral outgrowth assay (VOA). Of note, we used the same gating strategy for both blood and LN CD4 T cells (Supplementary Fig. 1c), and the mean percentage of total LN Tfh cells represented 65% of the total LN PD-1⁺ CD4 T cell population (Supplementary Fig. 1d,e).

Consistent with previous study, LN Tfh cells of viremic untreated individuals were expanded as compared to healthy individuals and their percentage dropped after prolonged ART to levels observed in healthy individuals (Supplementary Fig. 2a). We also investigated the expression of activation markers such as CD38, HLA-DR, and Ki-67 (Supplementary Fig. 2b) in the different LN memory CD4 T cell populations and observed significantly higher expression of these markers in Tfh cells as compared to the other LN CD4 T cell populations (*P* < 0.05) (Supplementary Fig. 2b).
Isolation of HIV-1 from blood and LN CD4 T cell populations

We performed a conventional virus outgrowth assay (VOA) using three single replicate cell dilutions, (10^5, 2X10^4 and 4X10^3 cells) for LN CD4 T cell populations and four single replicate cell dilutions (5X10^5, 10^5, 2X10^4 and 4X10^3 cells) for blood CD4 T cell populations. We used the highest common cell concentration (10^5 cells) to estimate and compare the capacity of the three sorted memory CD4 T cell populations, i.e. DN, single CXCR5+ and PD-1^{high}/Tfh, isolated from blood and LNs of long-term ART treated aviremic HIV-1-infected individuals to support active virus replication and production. We stimulated cell populations with anti-CD3 and anti-CD28 monoclonal antibodies (MAbs) and cultured cells with allogeneic CD8-depleted blood mononuclear cells isolated from HIV-uninfected individuals for 14 days (Fig. 1a). We first compared the levels of HIV-1 RNA and of the capsid protein P24 produced in the VOA supernatants at the highest common cell concentration i.e. 10^5 cells at day 0, 5 and 14 using previously validated assays^{17} (Fig. 1a). The cumulative data showed a significant increase in HIV-1 RNA levels in culture supernatants collected at day 14 as compared to day 5 of all memory CD4 T cell populations isolated from LNs and from single CXCR5+ and total PD-1^{+} memory CD4 T cell populations isolated from blood (P < 0.05) (Fig. 1b,c). The levels of HIV-1 RNA detected in day 5 and day 14 culture supernatants were significantly higher as compared to any other memory CD4 T cell populations isolated from blood or LN (P < 0.05; 60-73123 fold higher) (Supplementary Fig. 3a-d). Furthermore, only PD-1^{+}/Tfh memory CD4 T cells isolated from LNs showed a significant increase of HIV-1 P24 in culture supernatants collected at day 14 as compared to day 5 (P < 0.05) (Fig. 1d,e), suggesting a significant amplification of HIV-1 P24 production in LN PD-1^{+}/Tfh cells of long-term ART treated aviremic HIV-1-infected individuals. P24 production was not detected in the VOA culture supernatants at day 5 (Fig. 1d,e), whereas it was detected at day 14 in the culture supernatants of LN memory PD-1^{+}/Tfh cells in six out of the eleven long-term ART treated aviremic HIV-1-infected individuals and was border line positive in one out of the eleven individuals tested in blood memory PD-1^{+} CD4 T cells. The cumulative data indicated a significant increase (P < 0.05; 13-16 fold higher) of HIV-1 P24 levels in day 14 culture supernatants of LN PD-1^{+}/Tfh cells as compared to any other memory CD4 T cell populations isolated from blood or LN (Supplementary Fig. 3e,f). Of note, we have excluded that the differential viral outgrowth between cells from LN and blood has been influenced by different intracellular levels of atazanavir drug penetration in lymphoid tissue vs.
blood (Supplementary Fig. 4). Moreover, we did not observe a correlation between the frequencies of total LN PD-1\(^+\) CD4 T cells and the levels of HIV-1 RNA in the VOA culture supernatants while there was a trend towards correlation \((P = 0.05)\) with the levels of P24 (Fig. 1f.g). Interestingly, a strong correlation with both virologic measures was observed when the percentage of T\(h\) cells was used thus indicating that these cells were largely responsible for the production of HIV-1 RNA and P24 \((r = 0.64, P = 0.03\) and \(r = 0.77, P = 0.007\), respectively) (Fig. 1h,i).

HIV-1 RNA and P24 levels from LN PD-1\(^+\)/T\(h\) cells inversely correlate with duration of treatment

The levels of P24 detected in culture supernatants of LN PD-1\(^+\)/T\(h\) cells at day 14 correlated with the HIV-1 RNA levels \((r = 0.9352, P = 0.0001)\) (Fig. 2a) thus suggesting a direct association between HIV-1 RNA and P24 production. P24 production was detected only in culture supernatants with HIV-1 RNA levels greater than \(10^4/ml\) (Fig. 2a) thus indicating that a threshold level of HIV-1 RNA production is necessary for the detection of P24 under the experimental culture conditions used.

We next determined the relationship between the duration of treatment and the levels of HIV-1 RNA and P24 detected at day 14 in the culture supernatants of blood and LN memory CD4 T cell populations. The results indicated a strong inverse correlation between the levels of HIV-1 RNA detected in culture supernatants of LN PD-1\(^+\)/T\(h\) and LN single CXCR5\(^+\) CD4 T cells and duration of treatment \((r = -0.9015, P < 0.0001\) and \(r = -0.8142, P = 0.0018\), respectively; Fig. 2b). Similarly, the levels of P24 detected in culture supernatants of LN PD-1\(^+\)/T\(h\) cells inversely correlated with duration of treatment \((r = -0.8498, P = 0.0007; Fig. 2c)\).

Interestingly, HIV-1 RNA was consistently detected in culture supernatants of LN PD-1\(^+\)/T\(h\) cells of HIV-1-infected individuals treated for up to 14 years thus indicating that LN PD-1\(^+\)/T\(h\) cells may serve as a source of inducible virus after prolonged ART (Fig. 2b). However, P24 was detected only within the first 3 years after the initiation of treatment (Fig. 2c) and the lack of detection was associated with the decrease of HIV-1 RNA levels in the culture supernatants below \(10^3/ml\) (Figs. 1c and 2a). P24 was not detected in the VOA culture supernatants of blood memory CD4 T cell populations or LN PD-1\(^-\) memory CD4 T cell populations from the same individuals (Fig. 1d,e). Taken together, these data suggest that
detection of HIV RNA in VOA culture supernatants is the most sensitive parameter to be tested in blood and LN cell cultures of long-term ART treated individuals.

**Evaluation of infectious HIV-1 in blood and LN memory CD4 T cell populations**

We then assessed the presence of infectious virus in the VOA culture supernatants of blood and LN memory CD4 T cell populations using an *in vitro* HIV-1 infection assay. For these purposes, day 14 VOA culture supernatants of the highest common cell concentration *i.e.* $10^5$ cells, were used to inoculate activated CD8-depleted blood mononuclear cells isolated from HIV negative individuals. Cells were then cultured for 14 days, and culture supernatants were collected at day 0, 5 and 14 and assessed for the presence of HIV-1 RNA. The cumulative data of the *in vitro* infection assay showed a significant increase of HIV-1 RNA levels in culture supernatants collected at day 14 as compared to day 5 only from VOA culture supernatants of LN PD-1$^+$Tfh cells ($P < 0.05$) (Fig. 2d,e). Of note, none of the culture supernatants collected at day 0 had detectable levels of HIV-1 RNA (data not shown). We then compared the levels of HIV-1 RNA produced in culture supernatants of the *in vitro* infection assay from VOA culture supernatants of all memory CD4 T cell populations isolated from blood and LNs at day 14 (Fig. 2f,g). Interestingly, HIV-1 RNA was significantly more frequently detected in culture supernatants of LN PD-1$^+$Tfh cells (seven out of the eleven long-term ART treated aviremic HIV-1-infected individuals tested) as compared to any other memory CD4 T cell population isolated from blood or LNs ($P < 0.05$) (Fig. 2f). In addition, the levels of HIV-1 RNA detected in culture supernatants of LN PD-1$^+$Tfh cells were significantly higher as compared to any other memory CD4 T cell populations isolated from blood or LNs ($P < 0.05$) (Fig. 2g). Of note, HIV-1 RNA was detected (at the limit of detection) in culture supernatants of LN memory DN (one out of eleven individuals) and single CXCR5$^+$ (two out of eleven) CD4 T cell populations and in blood memory PD-1$^+$ (one out of the eleven) CD4 T cell populations (Fig. 2f). Finally, we determined the relationship between HIV-1 RNA levels detected in the VOA and those detected in the *in vitro* HIV-1 infection assay. The results indicated a strong correlation between these HIV-1 RNA levels in the culture supernatants of LN PD-1$^+$Tfh cells ($r = 0.8780$, $P = 0.0010$) (Fig. 2f). No significant association was observed between HIV-1 RNA levels from the VOA and the *in vitro* HIV-1 infection assay in blood CD4 T cell populations (Fig. 2h). Taken together,
these data suggest that LN PD-1⁺/Tfh cells of long-term ART treated aviremic HIV-1-infected individuals represent the major source of infectious HIV-1.

Detection of cell-associated RNA in blood and LN memory CD4 T cell populations

To determine the cell compartment(s) serving as sites of active and persistent HIV-1 transcription, we then assessed cell-associated HIV-1 RNA in blood and LN memory CXCR5⁻ PD-1⁺, CXCR5⁺PD-1⁻ and PD-1⁺ cells isolated from nine HIV-1-infected individuals (Table 1). Of note, blood samples were available for seven out of nine HIV-1-infected individuals. In addition to individuals #11 and #24 who were tested in the VOA, we studied an additional seven individuals treated with ART for a period ranging between 1 and 13 years. In eight of nine individuals tested, we detected cell-associated HIV-1 RNA in LN. These individuals were treated for up to 12 years (Fig. 3a,c). The levels of cell-associated HIV-1 RNA detected were significantly higher (3.3 to 33 fold) in LN memory PD-1⁺/Tfh cells as compared to blood or LN PD-1⁻ memory CD4 T cell populations (P < 0.05) (Fig. 3a). No significant associations were observed between levels of cell-associated RNA detected in blood memory CD4 T cell populations and duration of treatment (P > 0.05) (Fig. 3b). However, the levels of cell-associated HIV-1 RNA detected in LN PD-1⁺/Tfh cells inversely correlated with the duration of treatment (r = -0.7833, P = 0.017) (Fig. 3c). Notably, we observed a decrease in the levels of cell-associated HIV-1 RNA after at least 8 years of ART (Fig. 3c). The levels of cell-associated HIV-1 RNA detected in LN CXCR5⁺PD-1⁻ and CXCR5⁺PD-1⁺ cell populations were stable and detected up to 8 years after treatment but did not correlate with the duration of treatment (Fig. 3c). These results indicate that although prolonged ART may reduce over time the levels of cell-associated HIV-1 RNA, LN PD-1⁺/Tfh cells serve as a site of active and persistent virus transcription.

Histopathological changes associated with long-term ART in LN tissues

To determine whether the decrease in different virologic measures of HIV-1 replication was associated with changes in the LN structure and in the number and localization of PD-1⁺ CD4 T cells, we collected LN biopsies from five additional individuals after initiation of ART ranging between 0.3 and 12 years. The number of GCs/mm² ranged between 0.57/mm² and 0.05/mm² in individuals under ART for a period of time varying from 0.3 to 10 years (Fig. 4a,b). Only 1 primary follicle was found in Patient #87 treated for 12.2 years (Fig. 4a,b). These results
indicate substantial changes in LN structure associated with the duration of treatment reflecting a shift from an activation to a quiescent state in the LN tissue and a strong inverse correlation between the number of GCs/mm² and the duration of treatment (\(R^2 = 0.99\)) (Fig. 4a,b).

We then determined the distribution and the number of PD-1⁺ CD4 T cells in the LN tissue. Strongly PD-1⁺ cells were almost exclusively localized within GCs showing a polarized distribution in the light zone in the best developed (larger size) GCs, and few scattered isolated PD1⁺ cells were seen in mantle zones and in primary follicles (Fig. 4a). Comparison of serial immunostained sections showed that the density and distribution of PD1⁺ cells in GCs was essentially similar to those of CD4⁺ lymphocytes, while CD8⁺ cells accounted for only a small fraction of GC cells (Supplementary Fig. 5). Consistent with the reduction in GCs following ART, the number of PD-1⁺ GC T cells per tissue mm² decreased from 68.16 cells/mm² in Patient #92 treated for 0.3 years to 1.80 cells/mm² in Patient #87 treated for 12.2 years (Fig. 4a,c). As observed for GCs, the number of PD-1⁺ CD4 T cells negatively correlated with the duration of ART (Fig. 4a,c). Therefore, these results indicate that PD-1⁺ CD4 T cells are almost exclusively localized within GCs and their number progressively decreased after prolonged ART.

**LN PD-1⁺/Tfh cells are enriched in replication competent and infectious virus**

To estimate the frequencies HIV-1-infected cells containing inducible replication competent or infectious virus, the data generated from the single replicate cell dilutions (10³, 2.10⁴ and 4.10³ cells) of the eleven individuals using the conventional VOA were pooled together and frequencies were estimated using Extreme Limiting Dilution Assay¹⁸ (Fig. 5a). These analyses provide the average RNA-unit per million (RUPM)¹⁹ and Infectious Unit per million (IUPM)²⁰ for each memory CD4 T cell population in the eleven individuals studied. The results indicate that the average RUPM frequency following anti-CD3/anti-CD28 mAb stimulation of LN PD-1⁺/Tfh cells was significantly increased as compared to blood and LN PD-1⁺ memory CD4 T cell populations and represented about 37 cells containing replication competent virus per million of LN memory PD-1⁺/Tfh cells (\(P < 0.05\)) (Fig. 5b). The IUPM frequency in LN memory PD-1⁺/Tfh cells was also significantly increased as compared to any other blood and LN memory CD4 T cell population and represented about 6 cells containing infectious virus per million of LN memory PD-1⁺/Tfh cells (\(P < 0.05\)) (Fig. 5c), thus
demonstrating that LN PD-1*Tfh cells are enriched in cells containing replication competent and infectious virus.

The frequencies of inducible replication competent or infectious virus within each memory CD4 T cell population allowed us to estimate the relative contribution of blood and LN cell populations to the pool of cells containing replication competent and infectious virus in blood and LN compartments (Fig. 5d,e). We estimated the contribution of each CD4 T cell population using 1) the frequency of each cell population in each compartment and 2) the estimated numbers of CD4 T lymphocytes in different lymphoid organs21. The results indicate that LN PD-1*Tfh cells contributed the most to the pool of cells containing replication competent virus in the sum of blood and LN compartments and represented about 46% of the blood and LN cell reservoir producing replication competent virus (Fig. 5d).

Finally, we evaluated the contribution of blood and LN memory CD4 T cell populations to the pool of cells containing infectious virus in these compartments. The cumulative data show that LN PD-1*Tfh cells contributed the most to the pool of cells containing infectious virus in blood and LN compartments and represented about 96% of the blood and LN cell reservoir producing infectious virus (P < 0.05) (Fig. 5e). Taken together, these results demonstrate that LN PD-1*Tfh cells likely represent the major source of replication competent and infectious virus in long-term ART treated aviremic HIV-1-infected individuals.
Discussion

Our previous study\textsuperscript{11} has demonstrated that T\textsubscript{fh} cells serve as the primary CD4 T cell compartment for HIV-1 infection, replication and generation of infectious virus in viremic individuals. In the present study, we tested the hypothesis that T\textsubscript{fh} cells serve as the primary site for replication competent and infectious virus and active and persistent HIV-1 transcription in long-term ART treated aviremic individuals.

We used the conventional VOA to evaluate and compare the capacity of the three memory CD4 T cell populations \textit{i.e.} DN, single CXCR5\textsuperscript{+} and PD-1\textsuperscript{+}, isolated from blood and LNs of long-term ART treated aviremic HIV-1-infected individuals to support active virus replication and produce infectious virus. We showed that LN PD-1\textsuperscript{+} CD4 T cells (composed of about 65% T\textsubscript{fh} cells) are the major source of replication competent HIV-1 as compared to blood or LN PD-1\textsuperscript{−} memory CD4 T cell populations of long-term ART treated aviremic HIV-1 infected individuals.

A relationship has also been observed between the levels of HIV-1 RNA, P24 and the generation of infectious HIV-1 as well to transmit infection to CD4 T cells from HIV negative individuals. Furthermore, in contrast to the minimal decrease observed over time in the pool of latently HIV-1-infected blood CD4 T cells\textsuperscript{10}, there was a significant decrease overtime in both the levels of HIV-1 RNA and P24 particularly in the LN PD-1\textsuperscript{+}/T\textsubscript{fh} cell population. The present results may indicate that since LN PD-1\textsuperscript{+} CD4 T cells are mainly effector T cells, the CD4 T cell reservoir containing replication competent HIV-1 in LNs is much less stable as compared to blood and that ART has a major effect on reducing the size of the LN cell reservoir over time.

The demonstration that LN PD-1\textsuperscript{+}/T\textsubscript{fh} cells have the highest levels of cell-associated HIV-1 RNA indicates that this cell population is the primary site for HIV-1 transcription. Interestingly, cell-associated HIV-1 RNA was detected in individuals treated up to 12 years thus demonstrating that these cells are responsible for persistent HIV-1 transcription. The levels of cell-associated HIV-1 RNA in LN PD-1\textsuperscript{+}/T\textsubscript{fh} cells were stable for at least 5 years after ART and the initial decline was observed only after 8 years of treatment. The levels of cell-associated HIV-1 RNA in the other two LN memory CD4 T cell populations were significantly lower, stable and not influenced by the duration of treatment. These results suggest that the presence of cell associated HIV-1 RNA within CXCR5\textsuperscript{+}/PD-1\textsuperscript{−} and CXCR5\textsuperscript{−}/PD-1\textsuperscript{−} cells may reflect spill over of RNA production whereas active and persistent virus transcription within the PD-1\textsuperscript{+}/T\textsubscript{fh} cells.
Active and persistent virus transcription occurs preferentially within PD-1⁺/Tfh cells likely because of their greater state of activation and location in GCs that represent a privilege site for virus replication and infection. The persistence up to at least 12 years of cell-associated HIV-1 RNA in PD-1⁺/Tfh cells may help to explain why virus rebound is consistently observed after ART interruption. Although the present results do not provide formal demonstration for active and persistent HIV-1 replication, they support the existence of persistent HIV-1 replication during ART and are consistent with the recent study by Lorenzo-Redondo et al.

Long-term ART was also associated with a progressive shift from an activation to a quiescent state of the LN tissue as indicated by the progressive reduction in the number of GCs likely resulting from the progressive clearance of HIV-1 antigens from the GCs. Along the same line, the number of PD-1⁺/Tfh cells that were localized within GCs and predominantly responsible for active and persistent HIV-1 transcription greatly reduced after prolonged ART. Taken all together these results indicate that despite the lack of detection of viremia, active and persistent production of HIV-1 RNA occurs in the LN many years after ART. The persistence of active production of HIV-1 RNA is likely driven by the state of activation within the LN tissue and at least 10 years of therapy are needed to induce a quiescent state in the LN tissue and the substantial reduction in the pool of cells supporting active and persistent HIV-1 transcription during ART. Therefore, 10-15 years of ART may be needed to effectively suppress persistent virus replication in LNs.

We then evaluated the contribution of blood and LN memory CD4 T cell populations to the total pool of cells containing replication competent and infectious virus in these compartments and show that PD-1⁺/Tfh cells represented a major source of replication competent, i.e. about 46%, and of infectious, i.e. 96%, virus.

In conclusion, the present study has identified LN PD-1⁺/Tfh cells as the major site for the generation of replication competent and infectious HIV-1 and for active and persistent production of HIV-1 RNA in long-term ART treated HIV-1-infected individuals demonstrating that LN PD-1⁺/Tfh cells represent a major obstacle to HIV-1 functional cure. Therefore, the present results provide the scientific rationale for the development of interventional therapies targeting the elimination of PD-1⁺/Tfh cells using PD-1 antibody therapy.
Material and methods

Study group, ethics statement and cell isolation. Twenty seven HIV-1 infected adult volunteers (Table 1) and ten HIV-uninfected individuals were enrolled in the present study. No statistical method was used to predetermine sample size. The sample size was estimated based on a previously published study\textsuperscript{23}. The present study was approved by the Institutional Review Board of the Centre Hospitalier Universitaire Vaudois, and all individuals gave written informed consent. As inclusion criteria only individuals under antiretroviral therapy for more than 18 months with undetectable HIV-1 viremia (<50 HIV-1 RNA copies/mL) were enrolled for VOA analysis and individuals treated for different durations with ART were enrolled for the additional virological and histopathological analyses. As exclusion criteria, for VOA analysis individuals experiencing blips of viremia (>50 HIV-1 RNA copies/ml of plasma) within the last 12 months were not enrolled. Inguinal lymph node biopsies and blood samples were collected the same day. Blood mononuclear cells were isolated as previously described\textsuperscript{24} and lymph node mononuclear cells were isolated by mechanical disruption as previously described\textsuperscript{25}. Blood mononuclear cells and lymph node mononuclear cells were cryopreserved in liquid nitrogen. Since the inclusion criteria were the same for the individuals studied, there was no need for randomization or blinding.

Cell culture. Cells were cultured in RPMI (Gibco; Life Technologies) containing 10% heat-inactivated FBS (Institut de Biotechnologies Jacques Boy), 100 IU/ml penicillin and 100 µg/ml streptomycin (Bio Concept).

Antibodies. The following antibodies were used: APC-H7-conjugated anti-CD3 (clone SK7), PB- or FITC- or PE-CF594-conjugated anti-CD4 (clone RPA-T4), V450- conjugated anti-HLA-DR (clone (G46-6), PE-Cy7-conjugated anti-CD25 (clone M-A251), PerCP-Cy5.5-conjugated anti-CD69 (clone L78), purified coating anti-CD3 (clone UCHT1) and anti-CD28 (clone CD28.2) mAbs were purchased from BD (Becton Dickinson; CA, USA); and ECD-conjugated anti-CD45RA (clone 2H4) from Beckman Coulter (CA, USA).

Sorting of CD4 T-cell populations. The average number of LN mononuclear cells isolated was about 30 million cells and the percentage of LN memory CD4 T cells represented about 25% of total isolated LN mononuclear cells. On the basis of the average number of memory CD4 T cells available, it was not possible to sort individual PD-1\textsuperscript{+} cell populations, i.e. single PD-1\textsuperscript{+}CXCR5\textsuperscript{−}, PD-1\textsuperscript{int}CXCR5\textsuperscript{int} and PD-1\textsuperscript{high}CXCR5\textsuperscript{high}, and for these reasons the total PD-1\textsuperscript{+} CD4 T cell
population corresponding to about 9% of memory CD4 T cells was sorted. It should be also taken into account that to achieve a purity of >98% of the sorted cell populations and due to the loss of cells during sorting, about 150,000 cells per CD4 T cell population were consistently sorted for the VOA. Although the number of blood cells available for sorting experiments was much higher than that of LNs, the limiting factor was the very low percentage (about 0.5%) of PD-1\textsuperscript{high} cells within the blood memory CD4 T cell population. Cryopreserved blood and lymph node mononuclear cells were thawed and CD4 T cells were enriched using EasySep Human CD4 T-cell enrichment kit (StemCell Technologies, USA). CD4 T cells were then stained with Aqua LIVE/DEAD stain kit (4°C; 15 min) and then with anti-CD3 APC-H7, anti-CD4 FITC, anti-CD45RA ECD, anti-PD-1 PE-Cy7 and anti-CXCR5 PE (4°C; 25 min) and viable memory (CD45RA\textsuperscript{−}) CXCR5\textsuperscript{−}PD-1\textsuperscript{−}, CXCR5\textsuperscript{−}PD-1\textsuperscript{−} and PD-1\textsuperscript{+}CD4 T cell populations were sorted using FACS\textregistered Aria (Beckton & Dickinson). In all sorting experiments the grade of purity of the sorted cell populations was >98%.

**Viral outgrowth assay.** Different cell concentrations (five-fold limiting dilutions \textit{i.e.} 10\textsuperscript{5}, 2X10\textsuperscript{4} and 4X10\textsuperscript{3} cells for LN CD4 T cell populations and 5X10\textsuperscript{5}, 10\textsuperscript{5}, 2X10\textsuperscript{4} and 4X10\textsuperscript{3} cells for blood CD4 T cell populations) of sorted viable blood and lymph node memory CD4 T cells from HIV-1 infected individuals (\textbf{Table 1}) were cultured with allogeneic fresh CD8-depleted blood mononuclear cells (10\textsuperscript{6} cells/mL) from HIV-uninfected individuals and were stimulated for 3 days with anti-CD3/anti-CD28 MAb coated plates (10 \textmu g/mL) in presence of IL-2 (50 units/mL). Supernatants were collected at day 0, 5 and 14. Medium was replaced at day 5, and re-supplemented with cytokines. The presence of P24 antigen was assessed by ECL COBAS® HIV Ag (Roche; Switzerland). The presence of HIV-1 RNA was assessed by COBAS® AmpliPrep/TaqMan® HIV-1 Test (Roche; Switzerland). When required, culture supernatants were diluted (1/10) in basement matrix buffer (RUWAG Handels AG). Of note, COBAS® AmpliPrep/TaqMan® HIV-1 Test can detect HIV-1 group O and group M, clades A-H. Wells with detectable P24 (> 1 ECL unit/mL) were referred to as P24-positive wells. Wells with detectable HIV-1 RNA (> 20 HIV-1 RNA copies/mL) were referred to as HIV-1 RNA-positive wells. RUPM \textsuperscript{19} and IUPM\textsuperscript{20} were calculated by conventional limiting dilution methods using Extreme Limiting Dilution analysis (http://bioinf.wehi.edu.au/software/elda/) \textsuperscript{18}. The estimation of each population's contribution to the overall pool of HIV-1-infected cells was performed as follows: estimated contribution of memory CD4 T cell population A from compartment X to the
pool of cells containing replication competent virus in both blood and LN compartments = (%
of memory CD4 T cell population A from compartment X among total memory CD4 T cells
from compartment X) x (estimated RUPM freq. of memory CD4 T cell population A from
compartment X)) x [% of the estimated number of memory CD4 T cells present in compartment
A among the sum of the memory CD4 T cells present in both blood and LN] / [(sum of
contribution of memory CD4 T cell populations from compartment X to the pool of CD4 T cells
containing replication competent virus) x 100]. Estimated contribution of memory CD4 T cell
population A from compartment X to the pool of cells containing infectious virus in both blood
and LN compartments = [(% of memory CD4 T-cell population A from compartment X among
total memory CD4 T cells from compartment X) x (estimated IUPM freq. of memory CD4 T cell
population A from compartment X)) x [% of the estimated number of memory CD4 T cells
present in compartment A among the sum of the memory CD4 T cells present in both blood and
LN] / [(sum of contribution of memory CD4 T cell populations from compartment X to the pool
of CD4 T cells containing infectious virus) x 100]. The estimated number of total blood and LN
memory CD4 T cells was obtained from Ganusov et al. 21.

In vitro HIV-1 infection assay. CD8-depleted blood mononuclear cells isolated from HIV-
uninfected individuals were activated for 48 hours with anti-CD3/anti-CD28 micro-beads
(miltenyi) in complete RPMI medium supplemented with IL-2 (50 units/mL). Activated
allogeneic CD8-depleted blood mononuclear cells (10⁶ cells/mL) from HIV-uninfected
individuals were washed and exposed (6 hours, 37°C, 5% CO₂) to 100 µl VOA supernatants
collected at day 14. Following 6 hours exposure, cells were washed twice with complete medium
and cultured for 14 additional days in complete RPMI medium. The presence of infectious HIV-
1 particles was determined in the culture supernatants at day 0, 5 and 14 post inoculations as
assessed by HIV-1 RNA assay (COBAS® AmpliPrep/TaqMan® HIV-1 Test).

Quantification of Cell-associated RNA. Cell-associated HIV-1 RNA from individual samples
was extracted from 5X10⁵ sorted CD4 T cell populations and subjected to DNase treatment
(RNAqueous-4PCR Kit Ambion). RNA standard curves were generated after isolation and
quantification of viral RNA from supernatant of ACH2 culture as previously described26. One
step cDNA synthesis and pre-amplification were performed as previously described27 using the
following primers ULF1: 5'- ATG CCA CGT CGA AAC TCT GGG TCT CTC TDG TTA
GAC-3' UR1: 5'- CCA TCT CTC TCC TTC TAG C -3'. Real-time PCR was performed using

16
Roche light Cycler 480II using the following primers: LambdaT: 5' - ATG CCA CGT AAG CGA
AAC T - 3'; UR2: 5' - CTG AGG GAT CTC TAG TTA CC-3' and probes: 56-FAM 5' - CAC TCA
AGG/ ZEN/CAA GCT TTA TTG AGG C-3' IABkFQ 28.

Histopathology. Lymph nodes were measured, cut into slices which were fixed in B-plus or
formalin prior to routine processing and embedding in paraffin blocks. Four-micron sections
were cut and stained with hematoxylin and eosin. For each lymph node serial sections of the
most representative block were immunostained according to standard routine protocols using a
Ventana benchmark platform (Roche) using antibodies against CD20 (L26; Novocastra), CD3
(CD3-PS1; Leica), CD4 (SP35; Ventana), CD8 (C8/ 144B; DAKO), and PD1 (polyclonal Goat
IgG, RD Systems). PD1-immunostained slides were digitalized using a Hamamatsu Nanozoomer
1.0 Scanner (model C9600-01) at 40x with the NDPScan software (v 2.5.89). Scanning area and
focus points were set manually. Image analysis was performed with the Tissue IA specific
module of the Slidepath Software Digital Image Hub (DIH) (version 4.0.7). The surfaces of the
entire tissue section, and of individual germinal centers (manually circumscribed), were
measured. In order to quantify PD1-positive cells, we used the Measure Stained Cells Algorithm
at 20X which was set to take into account strongly stained (PD1+) cells, and nuclei as for
estimation of cell density.

Mass cytometry. Cryopreserved lymph node mononuclear cells were thawed, resuspended (10^6
cells/ml) in complete RPMI medium and stimulated or not with 100 ng/ml PMA (Sigma-
Aldrich) and 1 μg/ml ionomycin (Sigma-Aldrich) in the presence of golgi plug (BD) for 6 h at
37°C. Viability of cells in 500 μl of PBS was identified by incubation with 50 μM cisplatin
(Sigma-Aldrich) for 5 min at RT and quenched with 500 μl fetal bovine serum. Next, cells were
incubated (30 min; 4 °C) with metal conjugated antibodies directed against CD3, CD4, CD8,
CD45RA, CXCR5, PD-1, CCR7, CD27, CD28, HLA-DR, CD38, CCR5, CXCR4, CXCR3 and
CD57 (Fluidigm/DVS Science). Cells were washed and fixed (10 min; RT) with 2.4% PFA.
Cells were then permeabilized (45 min; 4°C) with Foxp3 Fixation/Permeabilization kit
(eBioscience), washed and stained (30 min; 4°C) with metal conjugated antibodies against Ki67,
Bcl-6, IFN-γ, TNF-α, IL-2, IL-21 (Fluidigm/DVS Science). Cells were washed and fixed (10
min; RT) with 2.4% PFA. Total cells were identified by DNA intercalation (1 μM Cell-ID
Intercalator, Fluidigm/DVS Science) in 2% PFA at 4 °C overnight. Labeled samples were
assessed by the CyTOF1 instrument that was upgraded to CyTOF2 (Fluidigm) using a flow rate
of 0.045 ml/min. Data were analyzed using Fluidigm Cytobank software package (Cytobank, Mountain View, CA).

Statistical analyses. Statistical significance (P values) was either obtained using two-tailed Chi-square analysis for comparison of positive proportions or using one-way ANOVA (Kruskal-Wallis test) followed by Wilcoxon Matched-pairs two-tailed Signed Rank test for multiple comparisons. Spearman rank test, linear regression or non-linear one-phase decay model were used for correlations. Finally, Statistical significance (P values) was obtained using Extreme Limiting Dilution analysis (http://bioinf.wehi.edu.au/software/elda/) or by unilateral or bilateral Z score for comparison of HIV-1-infected cell frequencies and contribution of each cell population to the total pool of infected cells, respectively. The analyses of multiple comparisons were taken into account for the calculation of statistical significance.
Acknowledgements.

We are grateful to Nicole Grandchamp, Patricia Pochon, Xavier Bron, Marion Graff, Aurore Crétignier, Rachel Mamin, Florence Bellanger, Line Leuenberger and Cyril André for technical assistance. We are grateful to the study manager Nils Rettby and to Deolinda Alves.

This work was funded by an educational grant of Bristol Myer Squibb to Dr. Matthieu Perreau.

The authors declare no competing financial interests.

Author Contributions.

R.B., F.P., A.N. performed the experiments; G. Pollakis performed and analyzed HIV sequencing, M.C. was responsible for patient recruitment, K.O. performed statistical analyses; J-M.C. performed lymph node biopsies; L.D.L. was in charge of immunohistochemistry experiments; G. Pantaleo and M.P. conceived the study, designed the experiments and wrote the manuscript.
References


14. Casazza, J.P., I; Ambrozak, D; Petrovas, C; Ferrando-Martinez, S; Del Rio-Estrada, P; Reyes-Teyran, G; Ruiz-Mateos, E; Mascola, J; Koup, RA Identification and characterization of individual HIV-infected CD4 T cells ex vivo. *Conference on Retroviruses and Opportunistic Infections Seattle, USA* (2015).


Figure legends

Figure 1. HIV replication and production of blood and LN memory CD4 T cell populations. (a) Schematic representation of the VOA. Levels of HIV-1 RNA in blood (b) or LN (c) memory CD4 T cell populations at day 5 and 14 (n = 11). Limit of detection of HIV-1 RNA was 20 HIV-1 RNA copies/ml. Undetectable values were arbitrarily defined as 10 HIV-1 RNA copies/ml. Levels of HIV-1 P24 in blood (d) or LN (e) memory CD4 T cell populations at day 5 and 14 (n = 11). Limit of detection of P24 was 1 ECL unit/ml. Correlation between the ex vivo percentage of LN memory CD4 T cell populations with the levels of HIV-1 RNA (f) or with the levels of HIV-1 P24 (g) produced in culture supernatants at day 14 of VOA of sorted LN memory CD4 T cell populations isolated from long-term treated aviremic HIV-1-infected individuals (n = 11). Correlation between the ex vivo percentage of LN CXCR5highPD-1high memory CD4 T cell populations with the levels of HIV-1 RNA (h) or with the levels of HIV-1 P24 (i) produced in culture supernatants at day 14 of VOA of sorted LN PD-1+ memory CD4 T cell populations isolated from long-term treated aviremic HIV-1-infected individuals (n = 11). CD4 T cell populations are color coded (b-i) and represented by a unique symbol (b-e). Red stars indicate statistical significance (P < 0.05) and was obtained using Wilcoxon Matched-pairs two-tailed Signed Rank test (b-e) or using Spearman rank test (f-i).

Figure 2. The levels of HIV-1 RNA and P24 from LN PD-1+/Tfh cells inversely correlate with duration of treatment. (a) Correlation between levels of HIV-1 RNA and P24 produced in day 14 VOA supernatants of sorted LN memory CD4 T cell populations (n = 11). Correlation between duration of treatment and levels of HIV-1 RNA (b) or HIV-1 P24 (c) produced in day 14 VOA supernatants of sorted LN memory CD4 T cell populations (n = 11). Levels of HIV-1 RNA in blood (d) or LN (e) memory CD4 T cell populations at day 5 and 14 post HIV-1 in vitro infection assay (n = 11). Proportion of HIV-1 infected individuals with detectable HIV-1 RNA (≥ 20 HIV-1 RNA copies/ml) (f) or levels of HIV-1 RNA (g) in blood and LN memory CD4 T cell populations at day 14 of in vitro HIV-1 infection assay (n = 11). (h) Correlation between HIV-1 RNA levels measured in VOA and in in vitro HIV-1 infection assay in supernatants of blood (h) or LN (i) memory CD4 T cell populations (n = 11). Undetectable values were arbitrarily defined as 10 HIV-1 RNA copies/ml (a-b; d-e; g-i). Histograms correspond to mean (f-g); red bars correspond to SEM (g). NA corresponds to not applicable (h). Red stars indicate statistical significance (P < 0.05) (e-g) and was obtained using Spearman rank test (a-c h-i),
Wilcoxon Matched-pairs two-tailed Signed Rank test (d-e; g), or using Chi square two tailed analysis (f).

**Figure 3. Detection of cell-associated HIV-1 RNA in LN PD-1⁺/Tfh cells of long-term ART treated aviremic HIV-1-infected individuals.** (a) Levels of cell-associated unspliced HIV-1 RNA (copies/million cells) in matched blood and LN CXCR5⁺PD-1⁺, CXCR5⁺PD-1⁻ and PD-1⁺ memory CD4 T cell populations isolated from treated aviremic HIV-1-infected individuals (n = 9). HIV-1-infected individuals are color coded. (b) Correlation between duration of ART and levels of cell-associated unspliced HIV-1 RNA of blood CXCR5⁺PD-1⁺, CXCR5⁺PD-1⁻ and PD-1⁺ memory CD4 T cell populations isolated from treated aviremic HIV-1 infected individuals (n = 7). (c) Correlation between duration of ART and levels of cell-associated unspliced HIV-1 RNA of LN CXCR5⁺PD-1⁺, CXCR5⁺PD-1⁻ and PD-1⁺ memory CD4 T cell populations isolated from treated aviremic HIV-1-infected individuals (n = 9). HIV-1 infected individuals are color coded (a). CD4 T-cell populations are color coded (b-e). Statistical significance (P values) was obtained using One-way ANOVA (Kruskal-Wallis test) followed by Wilcoxon Matched-pairs two-tailed Signed Rank test (a) or Spearman rank test for correlations (b-e).

**Figure 4. Histopathological changes associated with long-term ART in LN tissues.** (a) Representative examples of hematoxylin and eosin (upper panels) and anti-PD-1 immunohistochemistry (intermediate and lower panels) staining of LN of three treated aviremic HIV-1-infected individuals (#92, #86 and #87) at low magnification (upper and intermediate panels) and high magnification (lower panels). (b) Correlation between duration of ART and the number of GCs per mm² of LN tissue of aviremic HIV-1-infected individuals (n = 5). (c) Correlation between duration of ART and the number of PD-1-positive cells per mm² of LN tissue of aviremic HIV-1-infected individuals (n = 5). Correlations (R²) were calculated using a non-linear one-phase decay model according to the GraphPad Prism. Blue dotted curves correspond to the lower and upper confidence interval at 0.95.

**Figure 5. LN PD-1⁺/Tfh cells of long-term treated aviremic HIV-1 infected individuals are enriched in replication competent and infectious virus.** (a) Schematic representation of estimation of the mean inducible RUPM and IUPM frequencies. Estimated frequencies of inducible RUPM (b) and IUPM (c) frequencies in sorted blood and LN memory CD4 T cell populations (n = 11). Estimated contribution of blood and LN memory CD4 T cell populations to the pool of cells containing replication competent virus (d) or infectious virus (e) in both blood
and LN compartments \((n = 11)\). Estimated contribution of memory CD4 T cell population A from compartment X to the pool of cells containing replication competent or infectious virus in both blood and LN compartments = \([\% \text{ of population A from compartment X among total memory CD4 T cells from compartment X}] \times \text{(estimated RUPM or IUPM freq. of population A from compartment X)} \times \% \text{ of the estimated number of memory CD4 T cells present in compartment X among the sum of the memory CD4 T cells present in both blood and LN obtained from Ganusov et al}^{21} \] / \([\text{sum of contribution of memory CD4 T cell populations from compartment X to the pool of CD4 T cells containing replication competent or infectious virus}] \times 100\]. Histograms correspond to estimated mean (b-e) and red bars correspond to the lower and upper confidence interval at 0.95 (b-e). Red stars indicate statistical significance \((P < 0.05)\) and was obtained using ELDA, unilateral or bilateral Z score\(^{29}\).
Table 1.

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Age</th>
<th>Sex</th>
<th>Duration of HIV infection (years)</th>
<th>CD4 Cell Count at enrollment (cells/ul)</th>
<th>Viral Load at Enrollment (copies/ml)</th>
<th>Time on HAART (years)</th>
<th>HAART regimen*</th>
<th>Assays</th>
</tr>
</thead>
<tbody>
<tr>
<td>03</td>
<td>52</td>
<td>F</td>
<td>21</td>
<td>899</td>
<td>&lt;50</td>
<td>8</td>
<td>ATV/r,ABC,3TC</td>
<td>MC</td>
</tr>
<tr>
<td>04</td>
<td>60</td>
<td>M</td>
<td>3</td>
<td>424</td>
<td>&lt;50</td>
<td>2</td>
<td>TDF,FTC,EFV</td>
<td>VOA</td>
</tr>
<tr>
<td>06</td>
<td>36</td>
<td>M</td>
<td>6</td>
<td>966</td>
<td>&lt;50</td>
<td>3.9</td>
<td>ABC,3TC,ATV</td>
<td>CAR</td>
</tr>
<tr>
<td>07</td>
<td>36</td>
<td>M</td>
<td>6</td>
<td>760</td>
<td>&lt;50</td>
<td>6</td>
<td>ATV/r,ABC,3TC</td>
<td>VOA</td>
</tr>
<tr>
<td>08</td>
<td>48</td>
<td>M</td>
<td>8</td>
<td>359</td>
<td>&lt;50</td>
<td>2</td>
<td>ABC,3TC,EFV</td>
<td>VOA,MC</td>
</tr>
<tr>
<td>10</td>
<td>57</td>
<td>F</td>
<td>27</td>
<td>703</td>
<td>&lt;50</td>
<td>12</td>
<td>TDF,FTC,LPV</td>
<td>MC</td>
</tr>
<tr>
<td>11</td>
<td>54</td>
<td>M</td>
<td>17</td>
<td>934</td>
<td>&lt;50</td>
<td>12</td>
<td>ATV/r,FTC,TFD</td>
<td>VOA,CAR</td>
</tr>
<tr>
<td>12</td>
<td>41</td>
<td>F</td>
<td>9</td>
<td>1370</td>
<td>&lt;50</td>
<td>5</td>
<td>ATV/r,FTC,TFD</td>
<td>VOA</td>
</tr>
<tr>
<td>14</td>
<td>37</td>
<td>M</td>
<td>7</td>
<td>1267</td>
<td>&lt;50</td>
<td>2</td>
<td>TDF,FTC,EFV</td>
<td>VOA</td>
</tr>
<tr>
<td>23</td>
<td>55</td>
<td>M</td>
<td>10</td>
<td>430</td>
<td>&lt;50</td>
<td>2</td>
<td>TDF,FTC,EFV</td>
<td>VOA</td>
</tr>
<tr>
<td>24</td>
<td>51</td>
<td>M</td>
<td>9</td>
<td>520</td>
<td>&lt;50</td>
<td>3</td>
<td>TDF,FTC,EFV</td>
<td>VOA,CAR</td>
</tr>
<tr>
<td>25</td>
<td>55</td>
<td>M</td>
<td>15</td>
<td>500</td>
<td>&lt;50</td>
<td>14</td>
<td>ETR,FTC,TFD</td>
<td>VOA</td>
</tr>
<tr>
<td>35</td>
<td>35</td>
<td>M</td>
<td>2</td>
<td>368</td>
<td>&lt;50</td>
<td>1.5</td>
<td>ABC,3TC,EFV</td>
<td>VOA</td>
</tr>
<tr>
<td>39</td>
<td>42</td>
<td>F</td>
<td>9</td>
<td>459</td>
<td>&lt;50</td>
<td>7</td>
<td>ATV/r,FTC,TFD</td>
<td>VOA</td>
</tr>
<tr>
<td>42</td>
<td>45</td>
<td>M</td>
<td>11</td>
<td>949</td>
<td>&lt;50</td>
<td>7</td>
<td>ATV/r, TDF,FTC</td>
<td>CAR</td>
</tr>
<tr>
<td>60</td>
<td>43</td>
<td>F</td>
<td>22</td>
<td>692</td>
<td>&lt;50</td>
<td>8.9</td>
<td>EVG,FTC,EFV</td>
<td>CAR,MC</td>
</tr>
<tr>
<td>64</td>
<td>34</td>
<td>M</td>
<td>8</td>
<td>712</td>
<td>&lt;50</td>
<td>5</td>
<td>EVG,FTC,TFD</td>
<td>CAR</td>
</tr>
<tr>
<td>67</td>
<td>41</td>
<td>M</td>
<td>16</td>
<td>789</td>
<td>&lt;50</td>
<td>12.9</td>
<td>ABC,3TC,DTG</td>
<td>CAR</td>
</tr>
<tr>
<td>68</td>
<td>44</td>
<td>F</td>
<td>4</td>
<td>668</td>
<td>&lt;50</td>
<td>3.3</td>
<td>TDF,FTC,ETR</td>
<td>CAR</td>
</tr>
<tr>
<td>71</td>
<td>45</td>
<td>M</td>
<td>2</td>
<td>158</td>
<td>&lt;50</td>
<td>1</td>
<td>TDF,FTC,DTG</td>
<td>CAR</td>
</tr>
<tr>
<td>78</td>
<td>38</td>
<td>M</td>
<td>6</td>
<td>509</td>
<td>&lt;50</td>
<td>2.3</td>
<td>ATV/r,TDF,ETR</td>
<td>MC</td>
</tr>
<tr>
<td>80</td>
<td>48</td>
<td>F</td>
<td>22</td>
<td>490</td>
<td>&lt;50</td>
<td>1.2</td>
<td>LPV/r,3TC,AZT</td>
<td>IHC</td>
</tr>
<tr>
<td>82</td>
<td>51</td>
<td>M</td>
<td>22</td>
<td>1064</td>
<td>&lt;50</td>
<td>2</td>
<td>TDF,FTC,EFV</td>
<td>MC</td>
</tr>
<tr>
<td>85</td>
<td>44</td>
<td>M</td>
<td>23</td>
<td>1112</td>
<td>&lt;50</td>
<td>10</td>
<td>ATV,RAL,ABC,3TC</td>
<td>IHC</td>
</tr>
<tr>
<td>86</td>
<td>47</td>
<td>M</td>
<td>15</td>
<td>1025</td>
<td>&lt;50</td>
<td>8.4</td>
<td>ABC,3TC,EFV</td>
<td>IHC</td>
</tr>
<tr>
<td>87</td>
<td>56</td>
<td>M</td>
<td>13</td>
<td>593</td>
<td>&lt;50</td>
<td>12.2</td>
<td>TDF,FTC,ATV/r</td>
<td>IHC</td>
</tr>
<tr>
<td>92</td>
<td>37</td>
<td>M</td>
<td>4</td>
<td>14</td>
<td>&lt;50</td>
<td>0.3</td>
<td>ABC,DTG,3TC</td>
<td>IHC</td>
</tr>
</tbody>
</table>

*Abbreviations: ETR, etravirine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; ATV/r, atazanavir boosted with ritonavir; 3TC, lamivudine; ABC, abacavir; EFV, Efavirenz; EVG, Elvitegravir; RAL, Raltegravir; DTG, Dolutegravir; LPV/r, Lopinavir boosted with ritonavir; AZT, Zidovudine; VOA, Viral outgrowth assay; CAR, Cell-associated RNA; IHC, immunohistochemistry; MC, mass cytometry; ND, not determined.
Figure 1

a) Diagram showing the process of sorting blood memory (CD45RA+) CD4 T cell populations, HIV-1 infected CD4 T cells, and allogeneic CD8-depleted PBMCs with anti-CD3 and anti-CD28 antibodies. The timeline includes Day 0, Day 5, and Day 14, with readout involving HIV-1 RNA (RT-PCR) and P24 (ECL).

b) Graphs showing the levels of HIV-1 RNA (copies/ml) over time (days 5, 14) for CXCR5 PD-1 + and PD-1 + groups. Stars indicate significant differences.

c) Graphs showing the levels of HIV-1 RNA (copies/ml) over time (days 5, 14) for CXCR5 PD-1 + and PD-1 + groups. Stars indicate significant differences.

d) Graphs showing the levels of HIV-1 P24 (ECL unit/ml) over time (days 5, 14) for CXCR5 PD-1 + and PD-1 + groups. Stars indicate significant differences.

e) Graphs showing the levels of HIV-1 P24 (ECL unit/ml) over time (days 5, 14) for CXCR5 PD-1 + and PD-1 + groups. Stars indicate significant differences.

f) Scatter plot showing the correlation between the percentage of lymph node memory CD4 T cells and the levels of HIV-1 RNA (copies/ml) at day 14. The correlation coefficients are provided.

g) Scatter plot showing the correlation between the percentage of lymph node memory CD4 T cells and the levels of HIV-1 P24 (ECL unit/ml) at day 14. The correlation coefficients are provided.

h) Scatter plot showing the correlation between the percentage of lymph node memory CD4 T cells and the levels of HIV-1 RNA (copies/ml) at day 14. The correlation coefficients are provided.

i) Scatter plot showing the correlation between the percentage of lymph node memory CD4 T cells and the levels of HIV-1 P24 (ECL unit/ml) at day 14. The correlation coefficients are provided.
Figure 2
Figure 3

(a) Levels of cell-associated unspliced HIV-1 RNA in CD4+ lymph node T cell populations (copopulation cells).

(b) Levels of cell-associated spliced HIV-1 RNA in CD4+ lymph node T cell populations (copopulation cells).

(c) Levels of cell-associated unspliced HIV-1 RNA in CD4+ lymph node T cell populations (copopulation cells).

- **Blood**
- **Lymph node**

- **CXCR5**
- **PD-1**

- **DN**

**Statistical Details**:
- **DN**: $r = -0.704$, $P = 0.07$
- **CXCR5**: $r = 0.207$, $P = 0.0563$
- **PD-1**: $r = -0.4$, $P = 0.39$
- **CXCR5**: $r = -0.4$, $P = 0.0012$
- **PD-1**: $r = -0.78$, $P = 0.017$
Figure 5

(a) Limiting dilution format

Mean frequency of cells containing replication competent (RUPM) and infectious virus (UPM) per million cells determined using extreme limiting dilution assay.

(b) Frequency of cells containing replication competent cells (RUPM)

(c) Frequency of cells containing million RUPM cells (UPM)

(d) Contribution of each population to replication competent virus (%)

(e) Contribution of each population containing replication competent virus (%)

Legend:
- Blood
- LN

* indicates statistical significance.